MPM Oncology Impact Management »

Akero Therapeutics shares owned by MPM Oncology Impact Management

Quarter-by-quarter ownership of Akero Therapeutics (AKRO) shares owned by MPM Oncology Impact Management from 13F filings

Historical chart of MPM Oncology Impact Management investment in Akero Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Akero Therapeutics held by MPM Oncology Impact Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Akero Therapeutics by MPM Oncology Impact Management

Quarter filed Position value Share count Share price at filing
2024-06-30 $9.1M 386k 23.46
2024-03-31 $8.4M 333k 25.26

More positions owned by MPM Oncology Impact Management

Cullinan Therapeutics Common (CGEM)
Insmed Incorporated Common (INSM)
Olema Pharmaceuticals Common (OLMA)
iTeos Therapeutics Common (ITOS)
Crinetics Pharmaceuticals Common (CRNX)
Madrigal Pharmaceuticals Common (MDGL)
Iovance Biotherapeutics Common (IOVA)
Natera Common (NTRA)
Mirum Pharmaceuticals Common (MIRM)
Ultragenyx Pharmaceutical Common (RARE)
Moonlake Immunotherapeutics Class A Ord (MLTX)
Guardant Health Common (GH)
Disc Medicine Common (IRON)
Alkermes Common (ALKS)
Edgewise Therapeutics Common (EWTX)

View all positions for MPM Oncology Impact Management

Top funds holding Akero Therapeutics

Henderson Group
BlackRock
BlackRock
General Atlantic
T. Rowe Price Associates
Vanguard Group
State Street Corporation
Alliancebernstein
Perceptive Advisors
Boxer Capital
Geode Capital Management
Redmile Group
Point72 Asset Management
T. Rowe Price Investment Management
Baker Bros. Advisors

View all funds holding Akero Therapeutics